Kadmon Pharms Llc Drug Patent Portfolio
Kadmon Pharms Llc owns 1 orange book drug protected by 6 US patents Given below is the list of Kadmon Pharms Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12097202 | Methods of administering Belumosudil for treatment of chronic graft versus host disease | 14 Jul, 2042 | Active |
| US11311541 | Treatment of GVHD | 09 Apr, 2035 | Active |
| US10183931 | Rho kinase inhibitors | 07 Oct, 2033 | Active |
| US10696660 | Rho kinase inhibitors | 07 Oct, 2033 | Active |
| US9815820 | Rho kinase inhibitors | 07 Oct, 2033 | Active |
| US8357693 | Pharmacokinetically improved compounds | 30 Oct, 2029 | Active |
Latest Legal Activities on Kadmon Pharms Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kadmon Pharms Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jul, 2024 | US8357693 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US8357693 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2023 | US10696660 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8357693 |
|
Electronic Review
Critical
| 01 Jun, 2023 | US10696660 |
| Mail Certificate of Correction Memo | 31 May, 2023 | US10696660 |
| Post Issue Communication - Certificate of Correction | 30 May, 2023 | US10696660 |
| Certificate of Correction Memo | 26 May, 2023 | US10696660 |
|
Electronic Review
Critical
| 25 May, 2023 | US10183931 |
|
Electronic Review
Critical
| 25 May, 2023 | US9815820 |
| Mail Certificate of Correction Memo | 24 May, 2023 | US9815820 |
| Mail Certificate of Correction Memo | 24 May, 2023 | US10183931 |
| Certificate of Correction Memo | 23 May, 2023 | US10183931 |
| Post Issue Communication - Certificate of Correction | 23 May, 2023 | US9815820 |
| Post Issue Communication - Certificate of Correction | 23 May, 2023 | US10183931 |
Kadmon Pharms Llc Drug Patents' Oppositions Filed in EPO
Kadmon Pharms Llc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 28, 2023, by Elkington And Fife Llp. This opposition was filed on patent number EP13843426A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP13843426A | Feb, 2023 | SANDOZ AG | Granted and Under Opposition |
| EP13843426A | Feb, 2023 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
Kadmon Pharms Llc's Family Patents
Kadmon Pharms Llc Drug List
Given below is the complete list of Kadmon Pharms Llc's drugs and the patents protecting them.
1. Rezurock
Rezurock is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12097202 | Methods of administering Belumosudil for treatment of chronic graft versus host disease |
14 Jul, 2042
(17 years from now)
| Active |
| US11311541 | Treatment of GVHD |
09 Apr, 2035
(10 years from now)
| Active |
| US10183931 | Rho kinase inhibitors |
07 Oct, 2033
(8 years from now)
| Active |
| US10696660 | Rho kinase inhibitors |
07 Oct, 2033
(8 years from now)
| Active |
| US9815820 | Rho kinase inhibitors |
07 Oct, 2033
(8 years from now)
| Active |
| US8357693 | Pharmacokinetically improved compounds |
30 Oct, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rezurock's drug page